Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Grant

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
HIV Clinical Trials|April 16, 2015
Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adultsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
AIDS (London, England)|April 15, 2020
Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infectionNitya S Ramadoss, Nancy Q Zhao, Barbra A Richardson, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2010
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptasePhilip M Grant, Jonathan Taylor, Andrew B Nevins, et al.
HIV Clinical Trials|August 22, 2014
Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164Philip M Grant, Lauren Komarow, Alejandro Sanchez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 22, 2011
Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumoniaPaul E Sax, Lauren Komarow, Malcolm A Finkelman, et al.
The Journal of Antimicrobial Chemotherapy|July 8, 2019
A systematic review of the genetic mechanisms of dolutegravir resistanceSoo-Yon Rhee, Philip M Grant, Philip L Tzou, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|October 13, 2009
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of lifePhilip M Grant, Sarah Palmer, Eran Bendavid, et al.
HIV Clinical Trials|December 4, 2010
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Paul E Sax, Caroline E Sloan, Bruce R Schackman, et al.
AIDS Research and Human Retroviruses|April 29, 2015
Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected PatientsPhilip M Grant, Virginia Sheikh, Rebecca DerSimonian, et al.
Journal of Viral Hepatitis|January 9, 2021
Risk factors for difficult-to-treat hepatitis C virus genotype 4r in Rwanda and implications for elimination in sub-Saharan AfricaFabienne Shumbusho, Anne F Liu, Fredrick Kateera, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
HIV Clinical Trials|April 16, 2015
Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adultsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
AIDS (London, England)|April 15, 2020
Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infectionNitya S Ramadoss, Nancy Q Zhao, Barbra A Richardson, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2010
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptasePhilip M Grant, Jonathan Taylor, Andrew B Nevins, et al.
HIV Clinical Trials|August 22, 2014
Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164Philip M Grant, Lauren Komarow, Alejandro Sanchez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 22, 2011
Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumoniaPaul E Sax, Lauren Komarow, Malcolm A Finkelman, et al.
The Journal of Antimicrobial Chemotherapy|July 8, 2019
A systematic review of the genetic mechanisms of dolutegravir resistanceSoo-Yon Rhee, Philip M Grant, Philip L Tzou, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|October 13, 2009
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of lifePhilip M Grant, Sarah Palmer, Eran Bendavid, et al.
HIV Clinical Trials|December 4, 2010
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Paul E Sax, Caroline E Sloan, Bruce R Schackman, et al.
AIDS Research and Human Retroviruses|April 29, 2015
Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected PatientsPhilip M Grant, Virginia Sheikh, Rebecca DerSimonian, et al.
Journal of Viral Hepatitis|January 9, 2021
Risk factors for difficult-to-treat hepatitis C virus genotype 4r in Rwanda and implications for elimination in sub-Saharan AfricaFabienne Shumbusho, Anne F Liu, Fredrick Kateera, et al.
Pageof 4